In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Extra individuals are going to be enrolled with the discovered monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section https://clinicaleffectivenessofab79123.ltfblog.com/31163727/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison